인간유래 세포 소멸 인자와 그 수용체의 결합체인TRAIL-sDR5 결합체의 결정화에 의한 3차원 구조및 TRAIL 결실 돌연변이 단백질
    1.
    发明公开
    인간유래 세포 소멸 인자와 그 수용체의 결합체인TRAIL-sDR5 결합체의 결정화에 의한 3차원 구조및 TRAIL 결실 돌연변이 단백질 无效
    人类衍生因子的TRAIL-SDR5复合物的三维结构及其受体的X射线晶体学和TRAIL检测突变体蛋白

    公开(公告)号:KR1020020056565A

    公开(公告)日:2002-07-10

    申请号:KR1020000085947

    申请日:2000-12-29

    CPC classification number: C07K14/70575 C07K2299/00

    Abstract: PURPOSE: Provided are a three-dimensional structure of TRAIL-sDR5 complex of a human derived apoptotic factor and a receptor thereof by X-ray crystallography and TRAIL(TNF Related Apoptosis Inducing Ligand) deletion mutant protein. CONSTITUTION: TRAIL-sDR5 complex is prepared by mixing TRAIL protein of SEQ ID NO:1 and sDR5 protein of SEQ ID NO:2. It can be crystallization method comprises the steps of: injecting a solution consisting of 16% of polyethyleneglycol 3000, 0.05M of sodium acetate(pH 4.5), 0.22 M of sodium acetate and 0.6M of sodium chloride into a well; mixing the precipitation solution and protein solution in a mixing ratio of 1:1 on the surface of a cover slip; and covering the well with the cover slip to crystallize the protein.

    Abstract translation: 目的:提供通过X射线晶体学和TRAIL(TNF相关凋亡诱导配体)缺失突变蛋白的人源性凋亡因子及其受体的TRAIL-sDR5复合物的三维结构。 构成:通过混合SEQ ID NO:1的TRAIL蛋白和SEQ ID NO:2的sDR5蛋白来制备TRAIL-sDR5复合物。 结晶方法包括以下步骤:将由16%聚乙二醇3000,0.05M乙酸钠(pH4.5),0.22M乙酸钠和0.6M氯化钠组成的溶液注入孔中; 将沉淀溶液和蛋白质溶液以1:1的混合比混合在盖板的表面上; 并用盖子覆盖井,使蛋白质结晶。

    신규의 2,4-디플루오로벤즈아미드 유도체
    2.
    发明授权
    신규의 2,4-디플루오로벤즈아미드 유도체 失效
    新型2,4-二氟苯甲酰胺衍生物

    公开(公告)号:KR100713137B1

    公开(公告)日:2007-05-02

    申请号:KR1020010037547

    申请日:2001-06-28

    Abstract: 본 발명은 신규의 2,4-디플루오로벤즈아미드 유도체에 관한 것으로서, 더욱 상세하게는 HBV(Hepatitis B Virus) 증식 뿐만 아니라 HCV(Hepatitis C Virus) 증식을 억제하는 효과가 우수하여 B형 간염 및 C형 간염의 치료제 및 예방제로 유용한 비핵산계 화합물인 다음 화학식 1로 표시되는 2,4-디플루오로벤즈아미드 유도체와 그의 약학적으로 허용가능한 염, 그리고 그의 제조방법에 관한 것이다.

    상기 화학식 1에서 : R
    1 , R
    2 , R
    3 및 n은 각각 발명의 상세한 설명에서 정의한 바와 같다.

    2,4-디플루오로벤즈아미드 유도체, B형 간염, C형 간염, 치료제, 예방제

    카바페넴 항생물질의 중간체 및 그의 제조방법
    5.
    发明授权
    카바페넴 항생물질의 중간체 및 그의 제조방법 失效
    카바페넴항생물질의의간및및및및법법법

    公开(公告)号:KR100377448B1

    公开(公告)日:2003-03-26

    申请号:KR1020000046447

    申请日:2000-08-10

    Abstract: There is disclosed an azetidinone compound of the formula (I):wherein R is hydrogen, or a hydroxy protecting group, R1 and R2 are each independently alkyl of 1-15 carbon atoms, benzyl or cyclized together with the carbon atom to which they are attached to form a 5 or 6-membered cyclic hydrocarbon or a heterocyclic radical having one or two hetero ring atoms, said hetero ring atoms being selected from the group consisting of O and S; R3 is lower alkyl or -COO(lower alkyl) R4 is phenyl, or phenyl substituted with halogen, lower alkoxy or nitro which is useful as a synthetic intermediate to the 1'beta-methylcarbapenem-type antibacterial agent.

    Abstract translation: 公开了式(I)的氮杂环丁酮化合物:其中R是氢或羟基保护基,R 1和R 2各自独立地是1-15个碳原子的烷基,苄基或与它们所连接的碳原子一起环化 连接形成5或6元环烃或具有一个或两个杂环原子的杂环基,所述杂环原子选自O和S; R3是低级烷基或-COO(低级烷基),R4是苯基或被卤素,低级烷氧基或硝基取代的苯基,它可用作1'β-甲基碳代青霉烯类抗菌剂的合成中间体。

    신규의 2,4-디플루오로벤즈아미드 유도체
    6.
    发明公开
    신규의 2,4-디플루오로벤즈아미드 유도체 失效
    新的2,4-二氟硼酸衍生物

    公开(公告)号:KR1020030001167A

    公开(公告)日:2003-01-06

    申请号:KR1020010037547

    申请日:2001-06-28

    Abstract: PURPOSE: Provided are novel 2,4-difluorobenzamide derivatives which are excellent in inhibition of the growth of both HBV and HCV, and thus used as prevention and treatment agents for HBV hepatitis and HCV hepatitis. also, provided are their pharmaceutically acceptable salts and their manufacturing method. CONSTITUTION: The 2,4-difluorobenzamide derivative is represented by the formula(1), wherein R1 is C1-C4 linear or branched alkyl group, hydroxy group, a C2-C6 alkylamino group, a 4-sulfamoylphenyl group, or a saturated or unsaturated 5 or 6 membered hetero cycle having 1-2 of hetero atoms selected from N, O and S; R2 is H or a C1-C3 linear or branched alkyl group; or R1 and R2 are bound together with 1-2 of hetero atoms selected from N, O and S to form a saturated or unsaturated 5, 6 or 7 membered hetero cycle, wherein the hetero cycle is a C1-C4 linear or branched alkyl group, or substituted or unsubstituted with a C1-C3 hydroxyalkyl group; and R3 is a 5-indazolyl group; and n is an integer of 0-4.

    Abstract translation: 目的:提供对HBV和HCV的生长抑制优异的新型2,4-二氟苯甲酰胺衍生物,因此用作HBV肝炎和HCV肝炎的预防和治疗剂。 还提供了它们的药学上可接受的盐及其制造方法。 构成:2,4-二氟苯甲酰胺衍生物由式(1)表示,其中R1是C1-C4直链或支链烷基,羟基,C2-C6烷基氨基,4-氨磺酰基苯基或饱和或 具有1-2个选自N,O和S的杂原子的不饱和5或6元杂环; R2是H或C1-C3直链或支链烷基; 或R 1和R 2与1-2个选自N,O和S的杂原子结合在一起以形成饱和或不饱和的5,6或7元杂环,其中杂环是C 1 -C 4直链或支链烷基 或者被C1-C3羟烷基取代或未取代; 并且R 3是5-吲唑基; n为0-4的整数。

    알킬 시스-4-아미노-3-메톡시-1-피페리딘 카르복실레이트 염산염의 제조방법
    7.
    发明授权
    알킬 시스-4-아미노-3-메톡시-1-피페리딘 카르복실레이트 염산염의 제조방법 失效
    -4--3-1-顺式-4-氨基-3-甲氧基-1-哌啶羧酸烷基酯盐酸盐的制备方法

    公开(公告)号:KR100323652B1

    公开(公告)日:2002-03-29

    申请号:KR1019990047103

    申请日:1999-10-28

    Abstract: 본발명은알킬트란스-4-브로모-3-하이드록시-1-피페리딘카르복실레이트를출발물질로하여알킬트란스-4-브로모-3-벤조일아미노카르보닐옥시-1-피페리딘카르복실레이트, 알킬시스-1-벤조일-2-옥소-헥사하이드로-옥사졸로[5,4-c] 피리딘-5-카르복실레이트, 알킬시스-2-옥소-헥사하이드로-옥사졸로[5,4-c] 피리딘-5-카르복실레이트, 시스-1--부톡시카르보닐-5-에톡시카르보닐-2-옥소-헥사하이드로옥사졸로[5,4-c] 피리딘, 알킬시스-4--부톡시카르보닐아미노-3-하이드록시-1-피페리딘카르복실레이트및 알킬시스-4--부톡시카르보닐아미노-3-메톡시-1-피페리딘카르복실레이트의중간물질을거쳐시사프라이드의중간체인알킬시스-4-아미노-3-메톡시-1-피페리딘카르복실레이트염산염을제조하는방법에관한것이다. 본발명은종래기술과는달리모든반응이온화한조건에서진행되고각 단계마다특별히정제과정을필요로하지않으며위험한나트륨하이드라이드나수소가스를사용하지않아종래기술의단점을모두극복함으로써산업화가용이한장점을가지고있으며또한알킬시스-4-아미노-3-메톡시-1-피페리딘카르복실레이트를취급이불편하고순도(80% 이하)가떨어지는종래기술의액상형태와는달리공업적으로다루기쉬운고순도(98% 이상)의분말형태로얻을수 있는장점이있다.

Patent Agency Ranking